TaxuCardium Pharmaceuticals Group Inc. announced consolidated earnings results for the year ended December 31, 2013. For the year, revenues totaled $109,200 compared to $59,409 a year ago. Loss from operations was $6,906,249 against $8,293,821 a year ago.

Net loss from continuing operations totaling $6,906,803 or $1.04 per basic and diluted share compared to $8,227,114 or $1.39 per basic and diluted share a year ago. Net loss totaled $8,914,293 or $1.33 per basic and diluted share compared to $8,323,310 or $1.41 per basic and diluted share a year ago.